Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$761,000Cash on Hand
1.3mo Cash Runway
Follow MTNB by emailGet an email when MTNB reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about MTNB, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 3, 2026 ·
Restructuring Matinas BioPharma terminated its agreement with a former financial advisor, which had provided for up to $2.0 million in cash and up to $2.0 million in stock tied to certain business combinations. The Company paid the Advisor $562,500 in cash, and the parties exchanged mutual releases subject to certain contingencies. Form 8-K · SEC filing
Sep 28, 2026 ·
Listing Matinas BioPharma effected a one-for-fifteen reverse stock split of its common stock, effective 12:01 a.m. ET on September 28, 2026. The new CUSIP is 576810 402, and fractional shares will be paid in cash. Form 8-K · SEC filing
Sep 16, 2026 ·
Listing Matinas BioPharma's board approved a one-for-fifteen (1:15) reverse stock split of its common stock, effective 12:01 a.m. ET on September 28, 2026, with trading under MTNB on a split-adjusted basis and a new CUSIP of 576810 402. Fractional shares will be paid in cash. Form 8-K · SEC filing
Sep 4, 2026 ·
Listing Matinas received an NYSE American notice on August 31, 2026 that it is out of compliance with the Section 1003(a)(i) stockholders' equity standard, reporting $1.8 million against a $2.0 million minimum as of June 30, 2026. Form 8-K · SEC filing · Press release
Aug 13, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Nov 2022 · Phase 1/2 · Results Expected · Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT) Registry primary completion date, not a results date
Nov 2021 · Phase 2 · Results Expected · CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis Registry primary completion date, not a results date
Nov 2020 · Phase 2 · Results Expected · Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia Registry primary completion date, not a results date
May 2017 · Phase 2 · Results Expected · Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC) Registry primary completion date, not a results date
May 2015 · Phase 1/2 · Results Expected · A PK and PD Study of Two Formulations of Omega-3 One Gram Capsules Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not MTNB's own candidates): Amphotericin B, Fluconazole, Icosapent Ethyl.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
MTNB holds $761,000 in cash and short-term investments (as of Jun 30, 2026) and burns about $1.7M/quarter from operations,
an estimated runway of 1.3 months at that rate (BioRadar estimate, not company guidance).
Share count 1,113,528 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full MTNB picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MTNB and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.